Biohaven's Q3 update: FDA accepts Vyglxia filing, SK Biopharmaceuticals deal pendingOct 29Quarterly updateBiohaven Ltd.
Biohaven licenses IgG degrader portfolio to Ono Pharma for Asian marketsOct 15PartnershipBHV-1300Biohaven Ltd.
Biohaven advances degrader and epilepsy pipelines, reports Q2 2026 resultsAug 10Quarterly updateBHV-1300Biohaven Ltd.